Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending February 19, 2019. The document serves as a transaction notification reporting insider trading activities by Persons Discharging Managerial Responsibilities (PDMRs) and persons closely associated with them. The filing details the exercise of nil-cost options and subsequent share sales to meet tax liabilities under the Company's 2009 Deferred Annual Bonus Plan.
Key Financial Metrics
The filing does not contain consolidated financial statements, revenue, profit, cash flow, margins, debt, or liquidity metrics. It exclusively reports on specific equity transactions. Key transaction data includes:
- Instrument: Ordinary shares of 25 pence each (ISIN: GB0009252882).
- Transaction Date: February 18, 2019.
- Exercise Price: £0.0000 (Nil-cost options).
- Sale Price Range: Approximately £15.716 to £15.756 per share.
- Total Shares Exercised: 152,292 shares across four executives.
- Total Shares Sold for Tax: 71,705 shares across four executives.
Material Changes
This filing does not report material changes to the company's financial position, operations, or strategy compared to prior periods. It is a routine regulatory disclosure of executive compensation events occurring on a single date.
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, risk factors, or contingencies. The transactions were executed on the London Stock Exchange (XLON) to satisfy tax liabilities arising from the vesting of deferred bonus awards.
Important Facts for Investors
- Executive Participation: Transactions involved the CEO (Ms. E. Walmsley), CFO (Mr. S. Dingemans), President of Global Vaccines (Mr. R. Connor), and President of Global Affairs (Mr. P. Thomson).
- Net Share Retention: Executives exercised options for a total of 152,292 shares but sold 71,705 shares to cover taxes, resulting in a net increase in their holdings of 80,587 shares.
- Valuation Context: The sale prices (approx. £15.72–£15.76) reflect the market value of GSK shares on February 18, 2019.
- Plan Details: All options were granted on February 11, 2016, under the 2009 Deferred Annual Bonus Plan.